Genomic Valley Biotech Board of Directors
Get the latest insights into the leadership at Genomic Valley Biotech. Learn about the experienced professionals guiding the company's strategy and governance.
| Name | Position |
|---|---|
| Mr. Yogesh Agrawal | Managing Director |
| Mrs. Parul Agrawal | Non Executive Director |
| Mr. Ashok Kumar | Non Executive Director |
| Mr. Satendra Kumar Goyal | Ind. Non-Executive Director |
Genomic Valley Biotech Share price
GVBL
40.5
0.42 (-1.03%)Last updated on 4 Sep, 2025 | 15:28 IST
BUYSELL
Today's High
41.75
Today's Low
40.00
52 Week Low
37.89
52 Week High
108.15
The current prices are delayed, login to your account for live prices
LoginGenomic Valley Biotech FAQs
The board at Genomic Valley Biotech consists of experienced professionals, including Mr. Yogesh Agrawal , Mrs. Parul Agrawal , and others, overseeing the company’s strategic and corporate governance.
Directors at Genomic Valley Biotech are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.
As of the latest update, Mr. Yogesh Agrawal is the current chairman at Genomic Valley Biotech.
Executive directors at Genomic Valley Biotech are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.
Yes, Genomic Valley Biotech adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.
At Genomic Valley Biotech, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.